Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -255.05% is 71% above its 5-year average of -871.19%, near the high end of its 5-year range (-209031.45%–30.24%).
87.32% above its 12-month average of -2011.96%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2891.13%.
OPERATING MARGIN
-255.05%
OPERATING MARGIN AVG TTM
-2011.96%
OPERATING MARGIN AVG 3Y
-1451.98%
OPERATING MARGIN AVG 5Y
-871.19%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+87.32%
CURRENT VS 3Y AVG
+82.43%
CURRENT VS 5Y AVG
+70.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$113.77M
Operating Margin
-255.05%
TTM Avg
-2011.96%
3Y Avg
-1451.98%
5Y Avg
-871.19%
Market Cap
$113.89M
Operating Margin
-415175.00%
TTM Avg
-405687.50%
3Y Avg
-206404.23%
5Y Avg
-137602.82%
Market Cap
$114.46M
Operating Margin
-1054.82%
TTM Avg
-1057.23%
3Y Avg
-4752.68%
5Y Avg
-4082.42%
Market Cap
$112.94M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1243.96%
5Y Avg
-829.31%
Market Cap
$112.57M
Operating Margin
-1220.49%
TTM Avg
-1443.83%
3Y Avg
-998.11%
5Y Avg
-830.42%
Market Cap
$115.67M
Operating Margin
-265.64%
TTM Avg
-359.98%
3Y Avg
-411.27%
5Y Avg
-4203.28%
Market Cap
$116.76M
Operating Margin
-137.12%
TTM Avg
-134.83%
3Y Avg
-112.12%
5Y Avg
-90.73%
Market Cap
$110.30M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$117.76M
Operating Margin
0.00%
TTM Avg
-571.68%
3Y Avg
-414.68%
5Y Avg
-276.45%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $113.77M | -255.05% | -2011.96% | -1451.98% | -871.19% |
| Genelux Corporation (GNLX)vs › | $113.89M | -415175.00% | -405687.50% | -206404.23% | -137602.82% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -1054.82% | -1057.23% | -4752.68% | -4082.42% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | 0.00% | 0.00% | -1243.96% | -829.31% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -1220.49% | -1443.83% | -998.11% | -830.42% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | -265.64% | -359.98% | -411.27% | -4203.28% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -137.12% | -134.83% | -112.12% | -90.73% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | 0.00% | -571.68% | -414.68% | -276.45% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -754.08% | -1999.61% | -1887.55% | -2072.97% |
Gross Margin
99.9%
Operating Margin
-255.1%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -2891.13% |
| 2026-03-31 | -3042.13% |
| 2025-12-31 | -152.30% |
| 2025-09-30 | -53.78% |
| 2025-06-30 | -3920.47% |
| 2025-03-31 | -2976.89% |
| 2024-12-31 | -209031.45% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | -94.48% |
| 2024-03-31 | -4322.84% |
| 2023-12-31 | 30.24% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
